Ah, OK.........
SIGNALGENE WITHDRAWS ITS OFFER TO PURCHASE ALL OF THE SHARES OF NOVA MOLECULAR
Montreal, CANADA, September 18, 2000 - (Toronto Stock Exchange: SGI) - SignalGene Inc. today
announced that is has withdrawn its offer to purchase all of the shares of Nova Molecular Inc.
(NMI) announced on August 23, 2000. After completing its review of NMI, SignalGene concluded
that the proposed combination is not appropriate.
However, SignalGene intends to continue reviewing potential acquisitions as opportunities arise.
SignalGene is an integrated genomics-based drug discovery company. By combining
cutting-edge technologies in pharmacogenomics, functional genomics and drug design with
world-class scientific collaborations with university and hospital researchers, SignalGene is taking a
leading role in the conversion of genomic information into novel diagnostic and therapeutic
products for major human diseases. Current research programs target metabolic disorders
(obesity), women's health (breast cancer and osteoporosis), inflammatory disorders (psoriasis) and
neurodegenerative disorders (Alzheimer's disease). The Company generates short-term revenues,
through its GLP-based pharmacogenomics services and technology-based discovery
collaborations, while pursuing its internal research and development programs for partnering with
major pharmaceutical companies. The shares of the Company are listed on the Toronto Stock
Exchange under the symbol SGI.
SIGNALGENE : LEADER FOR THE MEDICINE OF TOMORROW
Information:
Michael Dennis, Ph.D.
President and CEO
SignalGene Inc.
(514) 850-2421 |
